Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Paul Tudor Jones Is Extremely Bullish About Asian Currencies

It isn’t very easy to garner any insights from Paul Tudor Jones’ 13F filings. He is usually a short term trader with hundreds of small meaningless positions. Fortunately, we have his latest investor letter and have an idea about what he is thinking. Tudor Jones currently thinks that Chinese and Asian currencies are significantly undervalued against the U.S. dollar. In order to keep their export driven economies humming, these countries opted to import dollar inflation. Jones estimates that Chinese RMB is 35% – 72% cheaper against the U.S. dollar than in 1993. This is what Jones suggests U.S. should do:

TUDOR INVESTMENT CORP

“It could intervene in the foreign exchange market against the Hong Kong dollar, and exert its influence on what is by definition a bilateral, not unilateral, exchange rate. This is no different from what Asia does everyday to the U.S. and would speed up RMB appreciation. Just as a matter of prudent reserve management, the U.S. could also intervene against other Asian currency suppressors to diversify its foreign exchange reserves.”

Paul Tudor Jones thinks Asian currencies are poised to appreciate significantly and he is betting accordingly. At the end of December, he had the following long positions in his portfolio:

Read the rest of the article here>>>

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!